Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02205827 · ClinicalTrials.gov registry record · NA

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

A NA study of Healthy, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT02205827: Completed NA study of Healthy, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.

NCT02205827 is a NA study of Healthy that has completed, run by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02205827, a NA study of Healthy, has completed, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to characterize the distribution and sources of variability in whole blood clotting time (WBCT) measurements in human blood collected from healthy volunteers by 5 different technicians.

Conditions Studied

Interventions

  • OTHER Single-arm

Study Locations (1)

Kansas

  • Quintiles Phase I Services, LLC - Overland Park

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2014-04
Est. Completion 2014-05
Phase NA

What the Registry Record Tells You About NCT02205827

The ClinicalTrials.gov registry entry for NCT02205827 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Single-arm is the first listed.

NCT02205827 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT02205827 about?

NCT02205827 is a clinical study titled "A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements". The purpose of the study is to characterize the distribution and sources of variability in whole blood clotting time (WBCT) measurements in human blood collected from healthy volunteers by 5 different technicians.

What is the current status of trial NCT02205827?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2014-04. Estimated completion is 2014-05.

What conditions does trial NCT02205827 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02205827?

The interventions under investigation include: Single-arm (OTHER).

Who is sponsoring clinical trial NCT02205827?

This trial is sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02205827 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.